BPMC - Stock Analysis & Overview

About Blueprint Medicines Corporation

Biotechnology

Healthcare

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma...

Blueprint Medicines Corporation Key Metrics

Market Cap: $6B
52 Weeks Low: $43.89
52 Weeks High: $121.90
P/B: 18.18x
P/E: -28.34x
P/S: 16.18x

Upcoming Events

BPMC Analyst Forecasts

‌

BPMC Financials

BPMC Income Statement Key Metrics

Revenue(TTM)362.80 M
Gross Profit(TTM)337.24 M
EBITDA(TTM)-346.00 M
Net Income(TTM)-205.49 M
EPS Diluted(TTM)-3.4200000000000004

Decode BPMC's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

BPMC earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of BPMC (0.902) is higher than the average of its peers (0.321).

Net Profit Margin vs Peers

Net profit margin ratio of BPMC (-2.033) is lower than the average of its peers (-0.327).

BPMC Return on Equity

See how efficiently BPMC generates profit for it's shareholders.

-388.17%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of BPMC (-3.882) is lower than the average of its peers (-0.419).

Return on Equity Growth

BPMC's Return on Equity has grown significantly over the past 10 years, increasing by over 13.06%.

BPMC Revenue Growth

See how BPMC has grown it's revenue over the past 10 years.

‌

Revenue Growth

BPMC's revenue has grown significantly over the past 10 years, increasing by over 0%.

Blueprint Medicines Corporation

Page title

Section title